Lab Matters Fall 2020 - Page 15

SARS-CoV-2 Antibody Detection with a Flexible , Scalable Format for High-Throughput Demands
ENVIRONMENTAL HEALTH
NCEH ’ s mission is to protect people ’ s health from environmental hazards that can be present in the air we breathe , the water we drink , and the food that sustains us .
SARS-CoV-2 , or to wait out the storm at home . CDC has released numerous guidance documents informing EH practitioners and the general public on how to prepare for this year ’ s severe weather , safe sheltering practices during COVID-19 and staying safe post-disaster . Additionally , CDC has disseminated timely information through webinars , updates to the Natural Disasters , Severe Weather , and COVID-19 websites , social media and direct emails to state public information officers .
As the trajectory of conventional EH work evolves throughout the pandemic , state , local and tribal public health systems and federal agencies are rapidly adapting and responding . CDC EH professionals are dealing with agency-wide activity reprioritization , working long incident response hours and facing an everchanging pandemic on top of hurricanes , wildfires and other emergencies . Changes due to COVID-19 are altering the landscape of public health work across all levels of government . For instance , technological advances are leading to digital transformation of EH services ( e . g ., virtual inspections , remote trainings and education ). Research and collaboration
US Public Health Service Captain Troy Ritter in April 2020 at the Shiprock Service Unit in New Mexico . In collaboration with Navajo Nation and Indian Health Service , the COVID-19 EH team provided technical assistance on water quality and access , epidemiology , and health communications . Photo : Troy Ritter ( CAPT , USPHS )
opportunities in emerging areas such as COVID-19 and air pollution and SARS-CoV-2 wastewater surveillance are gaining momentum . n

SARS-CoV-2 Antibody Detection with a Flexible , Scalable Format for High-Throughput Demands

Introducing the New Lumit Dx SARS-CoV-2 Immunoassay
The Lumit Dx SARS-CoV-2 Immunoassay is an in vitro diagnostic test designed to qualitatively detect antibodies to SARS-CoV-2 in serum or plasma . The assay can be easily adapted for automation on many liquid handlers to accommodate flexible testing demands and help accelerate testing of large patient populations . With combined experience of over 125 years , our team has scientific , technical and programmatic expertise working with a variety of third-party liquid handling platforms . We provide in-lab or remote assistance and support , including prewritten and custom scripts , protocols and custom formatting .
Fast , No-Wash , Easily Automated Workflow
Sample Plate
Add Lumit™ Dx CoV-2 LgBiT and Lumit™ Dx CoV-2 SmBiT to plate wells .
Add samples and controls to plate wells .
Incubate 30 minutes .
Add Lumit™ Dx Detection Reagent .
Incubate 3 minutes .
Learn More : promega . com / AntibodyTest
Measure luminescence .
Total assay time :
< 60 minutes
The Lumit Dx SARS-CoV-2 Immunoassay is a qualitative in vitro diagnostic test intended for the detection of antibodies to SARS-CoV-2 in serum or plasma , utilizing a novel , proprietary detection system .
The Lumit Dx SARS-CoV-2 Immunoassay is indicated in conjunction with clinical presentation and the results of other laboratory tests as an aid in identification of patients with recent or prior SARS-CoV-2 infection . Results from the test should not be used as the sole basis for diagnosis or to exclude SARS- CoV-2 infection . See clinical sensitivity data for days post symptom onset of positive results observed . Positive results will occur only after infection and are indicative of recent or prior infection . False positive results can occur due to cross-reactivity from pre-existing antibodies or other possible causes .
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities .
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments ( CLIA ) to perform high complexity tests .
For prescription use only . For in vitro diagnostic use only .
Reports to healthcare providers should include the following information : Negative results do not preclude acute SARS-CoV-2 infection . If acute infection is suspected , direct testing for SARS-CoV-2 is necessary . Results from antibody testing should not be used to diagnose or exclude acute SARS-CoV-2 infection . Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains , such as coronavirus HKU1 , NL63 , OC43 , or 229E . This test should not be used for screening of donated blood .
This test has not been reviewed by the FDA .
Lumit is a trademark of Promega Corporation . Products may be covered by pending or issued patents or may have certain limitations . Please visit our Web site for more information .
© 2020 Promega Corporation . 59069221 .
Fall 2020 LAB MATTERS 13